摘要
目的 :观察三七总皂苷对冠心病患者血清超氧化物歧化酶 (SOD)、过氧化脂质 (LPO)、组织型纤维蛋白溶酶原激活物 (tPA)及组织型纤维蛋白溶酶原激活物抑制剂 (PAI 1)的影响。方法 :将 45例患者分成 2组 ,三七总皂苷治疗组用三七总皂苷注射液 5 0 0mg加入 2 5 0ml液体中静滴 ,qd ,共 1周 ,余治疗同对照组。 结果 :治疗组血清SOD活力明显增高 (P <0 .0 1) ,LPO含量降低 (P <0 .0 1) ,对照组SOD活力及LPO含量用药前后无明显改变(P均 >0 .0 5 ) ,血清SOD的含量在治疗组用药前后和对照组皆无明显差别 (P均 >0 .0 5 )。三七总皂苷治疗后tPA明显高于治疗前 ,PAI 1明显低于治疗前 (P均 <0 .0 1) ,而对照组治疗前后无明显变化 (P均 >0 .0 5 )。结论 :三七总皂苷能升高冠心病患者SOD活力 ,降低LPO含量 ,提高纤溶功能。
Objective:To observe the effects of notoginsenoside on superoxide dismutase (SOD),lipid peroxide (LPO),tissue plasminogen activator (tPA) and plasminogen activator inhibitor (PAI-1) of patients with coronary diseases.Methods:The study was conducted in 45 patients.They were divided to receive once daily notoginsenoside injection 500mg given by infusion for 1 week or control agent.Results:The activity of serum SOD was significantly increased and LPO decreased in the active group and no such changes were observed in the control group.The tPA level was significantly increased and PAI-1 level was decreased in the active group and no such changes were observed in the control group.Conclusion:In patients with coronary diseases the notoginoside can increase their SOD activity,decrease their LPO level and enhance their fibrinolytic function.\;[
出处
《中国新药杂志》
CAS
CSCD
2000年第11期781-782,共2页
Chinese Journal of New Drugs
基金
湖北省九五攻关项目!的组成部分
编号 96 2P110 1
关键词
三七总皂苷
冠心病
过氧化脂质
SOD
TPA
Panax notoginseng
coronary disease
lipid peroxide
superoxide dismutase
tissue plasminogen activatD